News

1 to 9 of 25 results

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

09-12-2014

US biotech giant Amgen saw its shares rise 1.9% to $172.00 yesterday after the top US patent appeal court…

AmgenAnti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiosimilarsCubicinCubist PharmaceuticalsEnbrelGenericsHospiraLegalNovartisPatentsSandozUSA

Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion

08-12-2014

Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

Six hospital-acquired pneumonia drugs in late-stage development could generate $3.8bn by 2020

Six hospital-acquired pneumonia drugs in late-stage development could generate $3.8bn by 2020

09-09-2014

Six drugs currently in Phase III studies to treat hospital-acquired pneumonia would generate a total…

AmikacinAntibiotics and Infectious diseasesAstraZenecaBayerceftazidime-avibactamceftolozaneCubist PharmaceuticalsGSKHospital-acquired pneumoniaPharmaceuticalResearchUSA

Cubist Pharmaceuticals voluntarily recalls Cubicin lots in the USA

Cubist Pharmaceuticals voluntarily recalls Cubicin lots in the USA

06-08-2014

American biopharmaceutical company Cubist has issued a voluntary recall of certain lots of Cubicin (daptomycin…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsPhlebitisRegulationThromboembolismUSA

Fighting the biggest global threat

Fighting the biggest global threat

03-07-2014

Here's our take on the week's top stories.

AntibioticsAntibiotics and Infectious diseasesCubist PharmaceuticalsDavid CameronGlobal

Cubist’s Sivextro gets FDA approval for serious skin infections

Cubist’s Sivextro gets FDA approval for serious skin infections

22-06-2014

The US Food and Drug Administration has approved Cubist Pharmaceuticals’ Sivextro (tedizolid phosphate)…

Antibiotics and Infectious diseasesCubist PharmaceuticalsPharmaceuticalRegulationSivextroUSA

FDA accepts Cubist’s ceftolozane/tazobactam NDA with Priority Review

FDA accepts Cubist’s ceftolozane/tazobactam NDA with Priority Review

20-06-2014

The US Food and Drug Administration has accepted Cubist Pharmaceuticals’ New Drug Application for its…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsPharmaceuticalRegulationtazobactamUSA

1 to 9 of 25 results

COMPANY SPOTLIGHT

Menarini

Back to top